Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Patients
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are:
- To assess the safety and tolerability of cefiderocol after single-dose administration in
hospitalized paediatric patients 3 months to < 18 years of age with suspected or
confirmed aerobic Gram-negative bacterial infections
- To assess the pharmacokinetics (PK) of cefiderocol after single-dose administration of
cefiderocol in hospitalized paediatric patients 3 months to < 18 years of age with
suspected or confirmed aerobic Gram-negative bacterial infections
- To assess the safety and tolerability of cefiderocol after multiple-dose administration
in hospitalized paediatric patients 3 months to < 12 years of age with suspected or
confirmed aerobic Gram-negative bacterial infections
- To assess the PK of cefiderocol after multiple-dose administration in hospitalized
paediatric patients 3 months to < 12 years of age with suspected or confirmed aerobic
Gram-negative bacterial infections